This was successfully posted to your pofile.
This box will close automatically in a few seconds. Close this window
We don't have an e-mail address on file for you. To use AAFP Connection, you must have an e-mail address in our records. Click Here
FDA Seeks Docs' Help in Cracking Down on Misleading Drug Promotions
New Program Will Teach Physicians How to Spot, Report Violations
By News Staff
Thus, the agency's new Bad Ad Program aims to ensure that promotional information
- is accurate,
- balances the risks and benefits of a product,
- is consistent with prescribing information approved by the FDA, and
- includes only information that is supported by strong evidence from clinical studies.
"The Bad Ad Program will help health care providers recognize misleading prescription drug promotion and provide them with an easy way to report this activity to the agency," said Thomas Abrams, R.Ph., M.B.A., director of the DDMAC, in a May 11 news release.
FDA Commissioner Margaret Hamburg, M.D., said in a letter to health care professionals (2-page PDF; About PDFs) that the pharmaceutical industry spends nearly three times as much on advertising to health care professionals as it does on consumer-targeted advertising. Advertising aimed at health care professionals -- which occurs in places such as medical offices, hospitals, pharmacies and medical meetings -- often is beyond the scope of the DDMAC's surveillance efforts.
The DDMAC's monitoring of prescription drug promotion relies on review of industry materials submitted to the FDA, complaints filed by the pharmaceutical industry and field surveillance at large medical conventions, Hamburg said.
"While these efforts are effective, FDA's ability to monitor other promotional activities, which may occur in any number of settings, is limited," Hamburg said in her letter. "With the launch of the Bad Ad Program, FDA seeks to collaborate with health care professionals to address misleading promotion, wherever it may occur."
The FDA said examples of common violations include
- omitting or downplaying the risks associated with a product;
- overstating a product's effectiveness;
- promoting off-label, or unapproved, uses of products; and
- making misleading drug comparisons.
The FDA also has a campaign designed to educate consumers about misleading promotions.